Market Cap 384.78M
Revenue (ttm) 160.18M
Net Income (ttm) -69.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 6.90
Profit Margin -43.33%
Debt to Equity Ratio 1.15
Volume 2,300,500
Avg Vol 3,075,576
Day's Range N/A - N/A
Shares Out 265.37M
Stochastic %K 48%
Beta 0.35
Analysts Strong Sell
Price Target $5.40

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phospho...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 617 871 2098
Fax: 617 871 2099
Address:
245 First Street, Suite 1400, Cambridge, United States
GOLA_K
GOLA_K Jan. 31 at 3:40 AM
$AKBA Terminate the bastard JB, after spending 1.x billion, AKBA is worth of a 2 liter Coke!
0 · Reply
hsainu
hsainu Jan. 31 at 3:00 AM
$AKBA Change is in the air As jan 2026 ends and Feb 1st is upon us, all of USRC clinics are now at TIW Vafseo dosing. It is also nice to look back at the past (multipart thread) as some here are so interested in R/S and why it was so good to stop that and thankfully, and to fire the CFO who even proposed such a stupid notion. On April 11, 2023 was the vote stopping the R/S and then 5.6 million shares short out of 185 mm shares or 3%. Shares around $0.55. Shorts expected a reverse split vote to go through. It did not, so they were in a predicament which they never recovered from. They desperately needed a R/S, for example a 10:1 would allow 18.5 mm shares at $5.5 and the short interest would be at 560k. The moment that happens there will be enough longs to sell their shares giving the shorts enough leeway to cover their short. They needed longs to sell in droves to cover without share price rocketing up. Most longs would sell if the R/S went through, especially retail.
5 · Reply
Sal_The_Broke_Stalker
Sal_The_Broke_Stalker Jan. 31 at 12:58 AM
$AKBA Happy Friday Bulls!! It’s been awhile! And everything I can't remember As fucked up as it all may seem The consequences that are rendered I've stretched myself beyond my means
2 · Reply
dontbuytrash
dontbuytrash Jan. 31 at 12:48 AM
$AKBA To all my fellow delusional invesrors: I’ve heard a rumor that tomorrow at 11 a.m. the company will announce a buyout. The deal reportedly involves the company trading a decade of shareholder suffering for one bag of chips and a beer. Details pending...
3 · Reply
Noname2022
Noname2022 Jan. 30 at 10:25 PM
$AKBA Maybe cormedix will swoop in for renal assets at firesale prices… “what do we want to do next from a business development standpoint? We want something that’ll fit still synergistically, whether it’s with renal, hospital acute care, and eventually in the oncology space” https://www.investing.com/news/transcripts/cormedix-at-cantor-global-healthcare-conference-strategic-growth-and-diversification-93CH-4227060
3 · Reply
Mr_Pithy
Mr_Pithy Jan. 30 at 9:49 PM
$AKBA READING TEA LEAVES - (1)Co. intends to relocate headquarters in Sept. 2026. Why now? Akebia has been at same office since 2007? (2)John P. Butler, CEO amended & improved his severance package today in the event of a “change in control.” Butler hasn’t done so since March 2014. Why now, 12 years later? (3)Erik J. Ostrowski, CFO amended & improved his severance package today in the event of a “change in control.” Ostrowski hasn’t done so since June 2024. Why now, one & one half years later? (4)Why announce at same time, Akebia’s relocation plans, Messrs. Butler’s & Ostrowski’s improved severance packages in the event of a “change in control?” Answer - Overdue housekeeping? Or Answer - M&A activity? Other facts to consider - (a)significant M&A activity in sector; (b)NDD application pulled in best interests of shareholders; (c)Akebia’s pivot to differentiated pipeline; (d)2026 Vafseo revenue surge; (e)cash-on-hand. Good luck 🍀 to all of us.
5 · Reply
istockoz
istockoz Jan. 30 at 9:30 PM
$AKBA Moving HQ and Lab space by itself is has no meaning for M&A. Let's put some actions in perspective: 1) NDD Trials not accepted in order to preserve "shareholder value" 2) Purchased pipeline for rare disease research "a key valuation multiplier" 3) JB attended JPM Healthcare Conference in "ghost-mode" with a new investor presentation on hand 4) Provisions for executives modified focusing on "exit" or "termination" 5) New Office & Lab Space In my opinion these are actions of a company looking to increase valuation for a BO event. 2026 - Generate Cash from Vafseo & bring share price inline with DCF. 2027 - BO likely & 1-5 helps a clean sheet, simple valuation for the acquirer(s)
4 · Reply
Luckydips
Luckydips Jan. 30 at 9:11 PM
$AKBA im hoping no b/o at these prices ,don't think we could achieve 3 or 4 dollars 😬
3 · Reply
Userttt
Userttt Jan. 30 at 9:01 PM
$AKBA added to my position here and SLS this week. Will do the same next week
0 · Reply
refloS
refloS Jan. 30 at 8:51 PM
$AKBA As someone with zero MA background knowledge, I headed off to AI. Seems GPT's not having any of it.. Not intending to pour cold water on what's already been posted by some far more knowledgeable posters - just sharing what came back. I'm in the take it and run camp if it ever did happen!
2 · Reply
Latest News on AKBA
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts

Jan 13, 2026, 1:21 PM EST - 17 days ago

Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts


Akebia Announces Establishment of Rare Kidney Disease Pipeline

Dec 1, 2025, 7:00 AM EST - 2 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline


Q32 Bio Sells Complement Inhibitor ADX-097

Dec 1, 2025, 7:00 AM EST - 2 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

QTTB


Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 11:01 AM EST - 2 months ago

Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript


Akebia Therapeutics to Present at Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 3 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences


Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 10:21 AM EDT - 11 months ago

Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript


Q3 2024 Earnings: Hold Akebia Therapeutics

Nov 20, 2024, 3:31 PM EST - 1 year ago

Q3 2024 Earnings: Hold Akebia Therapeutics


GOLA_K
GOLA_K Jan. 31 at 3:40 AM
$AKBA Terminate the bastard JB, after spending 1.x billion, AKBA is worth of a 2 liter Coke!
0 · Reply
hsainu
hsainu Jan. 31 at 3:00 AM
$AKBA Change is in the air As jan 2026 ends and Feb 1st is upon us, all of USRC clinics are now at TIW Vafseo dosing. It is also nice to look back at the past (multipart thread) as some here are so interested in R/S and why it was so good to stop that and thankfully, and to fire the CFO who even proposed such a stupid notion. On April 11, 2023 was the vote stopping the R/S and then 5.6 million shares short out of 185 mm shares or 3%. Shares around $0.55. Shorts expected a reverse split vote to go through. It did not, so they were in a predicament which they never recovered from. They desperately needed a R/S, for example a 10:1 would allow 18.5 mm shares at $5.5 and the short interest would be at 560k. The moment that happens there will be enough longs to sell their shares giving the shorts enough leeway to cover their short. They needed longs to sell in droves to cover without share price rocketing up. Most longs would sell if the R/S went through, especially retail.
5 · Reply
Sal_The_Broke_Stalker
Sal_The_Broke_Stalker Jan. 31 at 12:58 AM
$AKBA Happy Friday Bulls!! It’s been awhile! And everything I can't remember As fucked up as it all may seem The consequences that are rendered I've stretched myself beyond my means
2 · Reply
dontbuytrash
dontbuytrash Jan. 31 at 12:48 AM
$AKBA To all my fellow delusional invesrors: I’ve heard a rumor that tomorrow at 11 a.m. the company will announce a buyout. The deal reportedly involves the company trading a decade of shareholder suffering for one bag of chips and a beer. Details pending...
3 · Reply
Noname2022
Noname2022 Jan. 30 at 10:25 PM
$AKBA Maybe cormedix will swoop in for renal assets at firesale prices… “what do we want to do next from a business development standpoint? We want something that’ll fit still synergistically, whether it’s with renal, hospital acute care, and eventually in the oncology space” https://www.investing.com/news/transcripts/cormedix-at-cantor-global-healthcare-conference-strategic-growth-and-diversification-93CH-4227060
3 · Reply
Mr_Pithy
Mr_Pithy Jan. 30 at 9:49 PM
$AKBA READING TEA LEAVES - (1)Co. intends to relocate headquarters in Sept. 2026. Why now? Akebia has been at same office since 2007? (2)John P. Butler, CEO amended & improved his severance package today in the event of a “change in control.” Butler hasn’t done so since March 2014. Why now, 12 years later? (3)Erik J. Ostrowski, CFO amended & improved his severance package today in the event of a “change in control.” Ostrowski hasn’t done so since June 2024. Why now, one & one half years later? (4)Why announce at same time, Akebia’s relocation plans, Messrs. Butler’s & Ostrowski’s improved severance packages in the event of a “change in control?” Answer - Overdue housekeeping? Or Answer - M&A activity? Other facts to consider - (a)significant M&A activity in sector; (b)NDD application pulled in best interests of shareholders; (c)Akebia’s pivot to differentiated pipeline; (d)2026 Vafseo revenue surge; (e)cash-on-hand. Good luck 🍀 to all of us.
5 · Reply
istockoz
istockoz Jan. 30 at 9:30 PM
$AKBA Moving HQ and Lab space by itself is has no meaning for M&A. Let's put some actions in perspective: 1) NDD Trials not accepted in order to preserve "shareholder value" 2) Purchased pipeline for rare disease research "a key valuation multiplier" 3) JB attended JPM Healthcare Conference in "ghost-mode" with a new investor presentation on hand 4) Provisions for executives modified focusing on "exit" or "termination" 5) New Office & Lab Space In my opinion these are actions of a company looking to increase valuation for a BO event. 2026 - Generate Cash from Vafseo & bring share price inline with DCF. 2027 - BO likely & 1-5 helps a clean sheet, simple valuation for the acquirer(s)
4 · Reply
Luckydips
Luckydips Jan. 30 at 9:11 PM
$AKBA im hoping no b/o at these prices ,don't think we could achieve 3 or 4 dollars 😬
3 · Reply
Userttt
Userttt Jan. 30 at 9:01 PM
$AKBA added to my position here and SLS this week. Will do the same next week
0 · Reply
refloS
refloS Jan. 30 at 8:51 PM
$AKBA As someone with zero MA background knowledge, I headed off to AI. Seems GPT's not having any of it.. Not intending to pour cold water on what's already been posted by some far more knowledgeable posters - just sharing what came back. I'm in the take it and run camp if it ever did happen!
2 · Reply
Psuedo_Doji
Psuedo_Doji Jan. 30 at 8:17 PM
$AKBA not all CFO's have M&A experience. Ours does. Hmmmmmmm...... Undeniably
1 · Reply
Elamenape2
Elamenape2 Jan. 30 at 7:40 PM
$AKBA Let’s just get it done.
0 · Reply
golddollar888
golddollar888 Jan. 30 at 7:31 PM
$AKBA Change-of-control provisions in executive severance agreements are far more important in an M&A context than office or headquarters arrangements.
0 · Reply
ae1213
ae1213 Jan. 30 at 7:22 PM
$AKBA the same pattern last few days - down in am, then up in pm. Smbdy vacuums up shares
0 · Reply
three_zero
three_zero Jan. 30 at 7:12 PM
$AKBA Mr. Grund is waiting for his updated agreement.
1 · Reply
golddollar888
golddollar888 Jan. 30 at 7:08 PM
$AKBA “Would a new 7+5 year headquarters lease be “anti-M&A”? This is a point many people misunderstand. The answer is no — in fact, it can make an acquisition more attractive. Why? Acquirers are usually more concerned about: • Lack of stable office and laboratory space • Employee attrition • Assets that look temporary or pieced together 📌 A clean, long-term, and cost-controlled headquarters lease: • ✔️ Lowers integration risk • ✔️ Makes financial modeling easier for an acquirer • ✔️ Does not hinder an acquisition (leases can be assumed or transferred) -from AI
1 · Reply
skagnetti13
skagnetti13 Jan. 30 at 6:57 PM
$AKBA The manipulation is staggering!
0 · Reply
Jeko44
Jeko44 Jan. 30 at 6:51 PM
$AKBA seems like their settling into ther next operating phase and not immediately preparing for M/A. Why would they sign a 7 year lease if that is happening soon? But they’ve cleaned up governance so a deal could, could I say, happen if the right offer appears.
1 · Reply
BeefStewart
BeefStewart Jan. 30 at 6:32 PM
$AKBA can someone help me to better understand the thesis here? Why has this retreated so much? Looks interesting at these levels.
1 · Reply
dontbuytrash
dontbuytrash Jan. 30 at 6:30 PM
$AKBA we are stuck until new news comes us that catch the shorts unexpectedly. For now we are bound to the 1.3-1.5 range. The ball is in Butler hands
0 · Reply
StockHawkZero
StockHawkZero Jan. 30 at 5:47 PM
$AKBA The usual "short any news" approach. However, this very much looks like set up for a management/organizational change.
0 · Reply
Fashtrades
Fashtrades Jan. 30 at 5:34 PM
$AKBA Greedy .. You ever post anything positive ? Or you just another short 🩳?
1 · Reply